• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024

    6/10/24 8:00:00 AM ET
    $AIM
    $AREC
    $CNSP
    $GRI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Coal Mining
    Energy
    Get the next $AIM alert in real time by email

    - Live video webcast presentations with Q&A

    - Preliminary schedule of participating companies now available at www.virtualinvestorco.com

    FRENCHTOWN, NJ / ACCESSWIRE / June 10, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Pitch Conference on June 17-18, 2024.

    For the event, participating companies will provide their "elevator pitch" and outline upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as time allows.

    The current schedule of participating companies is as follows:

    Monday, June 17

    • 10:00 AM ET: Adolore BioTherapeutics, Inc. (Private) - Webcast
    • 11:00 AM ET: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - Webcast
    • 12:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - Webcast
    • 1:00 PM ET: AIM ImmunoTech Inc. (NYSE:AIM) - Webcast
    • 4:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - Webcast

    Tuesday, June 18

    • 10:00 AM ET: Royalty Management Holding Corporation (NASDAQ:RMCO) - Webcast
    • 11:00 AM ET: GRI Bio, Inc. (NASDAQ:GRI) - Webcast
    • 12:00 PM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Webcast
    • 1:00 PM ET: American Resources Corporation (NASDAQ:AREC) - Webcast
    • 3:00 PM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - Webcast

    All investors and interested parties can access the event schedule and individual company webcast details at www.virtualinvestorco.com. Webcast replays will be made available shortly after the conclusion of the live event and will be accessible for 90 days.

    To access all Virtual Investor events, visit www.virtualinvestorco.com.

    About JTC Team

    JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

    Contact:

    Jenene Thomas
    JTC Team, LLC
    T: +1 (833) 475-8247
    [email protected]

    SOURCE: JTC Team, LLC



    View the original press release on accesswire.com

    Get the next $AIM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AIM
    $AREC
    $CNSP
    $GRI

    CompanyDatePrice TargetRatingAnalyst
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    Outlook Therapeutics Inc.
    $OTLK
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    Outlook Therapeutics Inc.
    $OTLK
    2/15/2024$3.00Neutral → Buy
    Chardan Capital Markets
    Outlook Therapeutics Inc.
    $OTLK
    1/25/2024Neutral → Buy
    Guggenheim
    Outlook Therapeutics Inc.
    $OTLK
    12/27/2023$5.00Equal Weight → Overweight
    CapitalOne
    More analyst ratings

    $AIM
    $AREC
    $CNSP
    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Chuang Emil

      4 - PALISADE BIO, INC. (0001357459) (Issuer)

      7/22/25 4:22:28 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Kellner Ted D

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      7/21/25 4:10:22 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Chuang Emil

      3 - PALISADE BIO, INC. (0001357459) (Issuer)

      7/17/25 5:17:06 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      6/23/25 4:35:31 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Klemp Walter V bought $250,000 worth of shares (675,675 units at $0.37), converted options into 12,740 shares and covered exercise/tax liability with 3,104 shares, increasing direct ownership by 1,176% to 743,607 units (SEC Form 4)

      4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

      6/23/25 4:35:11 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kellner Ted D bought $50,000 worth of shares (1,968,504 units at $0.03), increasing direct ownership by 196,850% to 1,969,504 units (SEC Form 4)

      4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

      4/23/25 4:35:16 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    SEC Filings

    See more
    • Palisade Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - PALISADE BIO, INC. (0001357459) (Filer)

      7/24/25 7:00:46 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CNS Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      7/22/25 4:39:58 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

      S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

      7/22/25 1:21:58 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

      ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the 8th Annual OIS Retina Innovation Summit being held on July 29, 2025 in Long Beach CA. Details for the presentations are as follows:Session: Innovation Showcase Presenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Tuesday, July 29, 2025, 8:35 – 9:35 AM PT For more information and to register for this event, please visit OIS Retina @ ASRS.About the Ophthalmology Innovation Summit (OIS) Retina Innovation

      7/24/25 9:00:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

      Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the "Existing Warrants") to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a redu

      7/23/25 8:00:00 PM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moleculin Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

      – Video webcast now available on-demand  HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Founder, President, CEO and Chairman of Moleculin, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. As part of the segment, Mr. Klemp dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast

      7/22/25 8:45:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

      H.C. Wainwright resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $4.00

      6/9/25 7:52:11 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin Biotech downgraded by Maxim Group

      Maxim Group downgraded Moleculin Biotech from Buy to Hold

      2/12/25 8:44:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on GRI Bio with a new price target

      H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

      12/9/24 7:50:37 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Leadership Updates

    Live Leadership Updates

    See more
    • Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

      40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. With over four decades of experience at Roche, Mr. Treve brings exceptional leadership and a deep understanding of global healthcare markets. He has held senior executive roles across diverse regions, including overseeing U.S. supply c

      7/17/25 8:25:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

      Veteran clinical leader with successful track record and experience to help guide the Company's clinical strategy in Fibrostenotic Crohn's Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors. Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nu

      7/9/25 8:45:00 AM ET
      $PALI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

      Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

      7/1/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

      SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

      12/17/24 4:11:23 PM ET
      $AIM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

      SC 13G/A - Moleculin Biotech, Inc. (0001659617) (Subject)

      11/14/24 5:12:06 PM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

      SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      11/14/24 4:55:26 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AIM
    $AREC
    $CNSP
    $GRI
    Financials

    Live finance-specific insights

    See more
    • Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

      LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

      5/15/25 4:01:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACLE" trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML  Regulatory and site selection progress to date supports interim data readout expected in the second half of 2025 Recently received European Medicines Agency (EMA) approval adds nine additional countries to the Company's ongoing MIRACLE trial; Authorization granted in all EU countries requested Company to host conference call and webcast today, May 14th at 8:30 AM ET HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug

      5/14/25 7:30:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

      HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referenci

      5/7/25 9:00:00 AM ET
      $MBRX
      Biotechnology: Pharmaceutical Preparations
      Health Care